INTerpath-001 Trial: Personalized mRNA Cancer Vaccine in High-Risk Melanoma
20 Posts Not to Miss from ESMO Congress 2026: Day 2
DeLLphi-305: Tarlatamab–Durvalumab Redefines First-Line Maintenance in Extensive-Stage SCLC
Inside ESMO 2026 with Amol Akhade
Paris Hilton and Kathy Hilton Host Pink Fundraiser for Breast Cancer Research in Beverly Hills
Lacy Hubbard: Rwanda Reaches a Major Milestone in HPV Screening With Mission 2027
Amol Akhade and Mohana Murali Kolluri at COGC 2026: The Cancer Care Gap in Asia-Pacific
London Global Cancer Week 2026 Speakers
OncoDaily GI is the dedicated GI cancer platform of OncoDaily, focused on the rapidly evolving field of gastrointestinal oncology. It covers the full spectrum of GI malignancies, including colorectal, anal canal, gastric, gastroesophageal junction (GEJ), esophageal, small bowel, pancreatic, hepatocellular, and biliary tract cancers. Through OncoDaily GI, readers can follow the latest clinical trial developments, ongoing research, FDA and EMA approvals, guideline updates, emerging therapies, advances in biomarkers and precision oncology, major conference findings, and interviews with leading experts in the field.
![COMPETE Trial: [177Lu]Lu-Edotreotide Prolongs PFS vs Everolimus in Advanced GEP NETs](https://oncodaily.com/pub/uploads/2026/07/COMPETE-Trial-800x450.webp "COMPETE Trial: [177Lu]Lu-Edotreotide Prolongs PFS vs Everolimus in Advanced GEP NETs 11")
